ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
Binding properties of marine sulfated glycans to coagulation (co)-factors using surface plasmon resonance spectroscopy. [PDF]
Al Ahmed H, Pomin VH.
europepmc +1 more source
In-vitro ACE-1 Inhibitory Activity of <i>Coleus scutellarioides</i> Benth (Mayana) Crude Ethanolic Dehydrated Leaf Extract. [PDF]
Parlocha EMD +4 more
europepmc +1 more source
Increased soluble CD200 in serum of SLE patients does not reflect disease activity or affect CD200R1 function in T cells. [PDF]
Kaan ED +4 more
europepmc +1 more source
Macroalgal Peptides with Predicted α-Glucosidase Inhibitory Activity: Preparation and Molecular Docking. [PDF]
Ghelichi S +4 more
europepmc +1 more source
Green synthesis of nisin-loaded pectin based silver nanoparticles and their antimicrobial and biosafety assessment. [PDF]
Jiang YQ +6 more
europepmc +1 more source
The Virtual Brain links transcranial magnetic stimulation evoked potentials and inhibitory neurotransmitter changes in major depressive disorder. [PDF]
Hofsähs T +5 more
europepmc +1 more source

